Results 141 to 150 of about 4,732 (172)

Involvement of hypothalamic peptides in the anorectic action of the CB1 receptor antagonist rimonabant (SR 141716)

European Journal of Neuroscience, 2009
Brian Oldfield, Iain Mcgregor
exaly  

Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon

International Journal of Cancer, 2009
Maurizio Bifulco, Antonietta Santoro, Francesca Borrelli   +2 more
exaly  

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Lancet, The, 2005
André Scheen, Luc Van Gaal
exaly  

Rimonabant during early pregnancy

International Journal of Gynecology & Obstetrics, 2010
Guillaume, Ducarme, Pierre-François, Ceccaldi, Hélène, Pejoan, Dominique, Luton   +3 more
openaire   +2 more sources

The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction

Basic Research in Cardiology, 2009
Sean M Davidson, , Shiang Yong Lim
exaly  

Rimonabant: Unique and Promising

Preventive Cardiology, 2005
openaire   +2 more sources

Rimonabant: obituary for a wonder drug

The Lancet, 2010
Boekholdt, S. Matthijs, Peters, Ron J. G.   +1 more
openaire   +2 more sources

The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile

Diabetes, Obesity and Metabolism, 2005
Bart Staels
exaly  

Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors

Journal of the American College of Cardiology, 2006
Christopher Cannon
exaly  

RIMONABANT

2014
openaire   +1 more source